Arexvy RSV vaccine,
does it really help with Prevention of RSV lower respiratory tract disease and severe disease in adults aged 60 years or older?
research showsArexvy is rated B because it prevents RSV lower respiratory tract disease and severe disease in adults aged 60 years or older. In the approximately 25,000-participant AReSVi-006 phase 3 trial, first-season RT-PCR-confirmed RSV lower respiratory tract disease occurred in 7 vaccine recipients and 40 placebo recipients, for 82.6% efficacy, while efficacy against severe disease was 94.1%. One-dose cumulative efficacy remained 67.2% over two seasons. The approximately 75% estimate from independent real-world research pooled Arexvy and Abrysvo and did not separate Arexvy-specific effectiveness. Product-specific randomized evidence nevertheless comes from one GSK program, event counts were small, and protection declined over time, producing upper B rather than A.
ads claimThe advertised 82.6% figure is a first-season relative risk reduction; it does not mean complete prevention or an 82.6-percentage-point reduction in every person's absolute risk. Cumulative efficacy declined over two seasons, while mortality prevention and optimal revaccination timing are separate questions.
Useful facts when choosing a product
- Arexvy is an intramuscular vaccine containing RSV prefusion F protein and the AS01E adjuvant, with a reconstituted single dose of 0.5 mL.
- The latest United States indication includes adults aged 60 years or older and adults aged 18 through 59 years at increased risk, although national recommendations can be narrower and depend on age and underlying disease.
- Injection-site pain, fatigue, myalgia, headache, and arthralgia are common and are usually transient and mild to moderate.
- Postmarketing observational evidence prompted a warning about Guillain-Barré syndrome during the 42 days after vaccination, and progressive weakness, tingling, or walking difficulty requires urgent assessment.
What the research actually shows
Papi and colleagues' 2023 international phase 3 trial followed 12,467 vaccine and 12,499 placebo recipients for a median of 6.7 months. Lower respiratory disease occurred in 7 versus 40 participants, and efficacy against severe disease was 94.1%. Ison and colleagues' 2024 extension of the same trial found cumulative two-season efficacy of 67.2% against lower respiratory disease and 78.8% against severe disease after one dose, showing persistence with attenuation. Fry and colleagues' independent 2025 electronic-record analysis reported about 75% effectiveness from pooled Arexvy and Abrysvo recipients and did not separate Arexvy-specific effectiveness. Rare Guillain-Barré signals require separate safety surveillance.
Why this is classified as B (79)
An approximately 25,000-person trial substantially reduced direct RT-PCR-confirmed lower respiratory and severe disease, with two-season and independent real-world evidence supporting the direction. Product-specific randomized evidence remains a single GSK program, event counts are small, and efficacy attenuates, giving upper B with 79 points. Rare GBS and common reactogenicity remain separate safety issues.
Counterpoint. Even with a large relative effect, absolute benefit depends on age, cardiopulmonary disease, immune status, and exposure. Timing should follow current national guidance and individual risk.
Rejudgment record. New verdict — Accepted the direct RT-PCR-confirmed RSV lower respiratory and severe disease outcomes in an approximately 25,000-person randomized trial and supportive two-season and independent real-world evidence, while accounting for absent product-specific independent large randomized confirmation, few events, and waning efficacy
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of RSV lower respiratory tract disease in adults aged 60 years or older | B | An approximately 25,000-person direct trial and real-world data are positive, but no product-specific independent randomized trial exists. |
| Prevention of severe RSV lower respiratory tract disease in adults aged 60 years or older | B | The effect size is large, but event counts and precision are limited. |
| Prevention in older adults with cardiopulmonary or metabolic comorbidity | B | Prespecified subgroups and real-world immunocompromised groups support the direction, but precision is low in some subgroups. |
| Multiseason durability after one dose | B | Direct two-season evidence is positive, but protection declined from 82.6% to 67.2% cumulatively. |
| Prevention of RSV-related death | ? | There are too few events to estimate an effect on RSV-related death reliably. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Papi A et al. 2023 AReSVi-006 | International randomized observer-blind placebo-controlled phase 3 trial | 24,966 | GSK Biologicals | First-season RT-PCR-confirmed RSV lower respiratory tract disease and severe disease | Lower respiratory disease occurred in 7 versus 40 participants, for 82.6% efficacy; severe-disease efficacy was 94.1%. | Pivotal large direct clinical-outcome evidence |
| Ison MG et al. 2024 | Two-season randomized extension analysis of AReSVi-006 | 25,000 | GSK | Cumulative two-season RSV lower respiratory and severe disease after one dose | Cumulative two-season efficacy was 67.2% against lower respiratory disease and 78.8% against severe disease. | Direct durability evidence from the same manufacturer cohort |
| Fry SE et al. 2025 | Independent large test-negative case-control and self-controlled safety study | 4,746,518 | United States NIH support with no sponsor role in analysis | RSV respiratory illness, emergency care, hospitalization, and GBS | Overall RSV vaccine effectiveness was about 75.1%; estimated excess GBS for the Arexvy class was 5.2 per million doses. | Independent real-world confirmation with observational mixed-product limitations |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Arexvy RSV vaccine x prevention of RSV lower respiratory tract disease and severe disease in adults aged 60 years or older — Evidence Grade B·79. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/arexvy-older-adults-rsv-lower-respiratory-disease-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.